Last reviewed · How we verify

Liposomal bupivacaine right injection

Prisma Health-Upstate · FDA-approved active Small molecule Quality 5/100

Liposomal bupivacaine right injection is a Small molecule drug developed by Prisma Health-Upstate. It is currently FDA-approved. Also known as: Exparel Right.

At a glance

Generic nameLiposomal bupivacaine right injection
Also known asExparel Right
SponsorPrisma Health-Upstate
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Liposomal bupivacaine right injection

What is Liposomal bupivacaine right injection?

Liposomal bupivacaine right injection is a Small molecule drug developed by Prisma Health-Upstate.

Who makes Liposomal bupivacaine right injection?

Liposomal bupivacaine right injection is developed and marketed by Prisma Health-Upstate (see full Prisma Health-Upstate pipeline at /company/prisma-health-upstate).

Is Liposomal bupivacaine right injection also known as anything else?

Liposomal bupivacaine right injection is also known as Exparel Right.

What development phase is Liposomal bupivacaine right injection in?

Liposomal bupivacaine right injection is FDA-approved (marketed).

Related